Literature DB >> 28692877

Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.

Joana B Pereira1, Eric Westman2, Oskar Hansson3.   

Abstract

The aggregation and deposition of amyloid-β (Aβ) peptides into plaques is an early event in Alzheimer's disease (AD), which is followed by different aspects of neurodegeneration that can be measured in the cerebrospinal fluid (CSF) or plasma using neurofilament light (NFL), neurogranin (Ng), total Tau (T-Tau), and phosphorylated tau (P-Tau) levels. The relationship between these biomarkers and regional brain atrophy across the different stages of AD remains largely unexplored. In this study, we assessed whether NFL, Ng, T-Tau, and P-Tau levels in CSF and NFL in plasma are associated with cortical thinning and subcortical volume loss in cognitively normal, mild cognitive impairment, and AD subjects with and without Aβ pathology. Our main findings showed that CSF NFL levels were associated with brain atrophy in all groups, but plasma NFL only correlated with atrophy in symptomatic cases. In contrast, Ng was associated with regional brain atrophy only in individuals with Aβ pathology. Altogether, our main findings suggest that Ng is strongly associated with Aβ pathology, whereas NFL is more unspecific.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cortical thickness; Neurofilament light; Neurogranin; Subcortical volumes; Tau

Mesh:

Substances:

Year:  2017        PMID: 28692877     DOI: 10.1016/j.neurobiolaging.2017.06.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  37 in total

1.  Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.

Authors:  Silke Kern; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Ingmar Skoog; Margda Waern; Clinton E Hagen; Argonde C van Harten; David S Knopman; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  JAMA Neurol       Date:  2019-02-01       Impact factor: 18.302

Review 2.  Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update.

Authors:  Sun Ah Park; Yu Jung Jang; Min Kyoung Kim; Sun Min Lee; So Young Moon
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

3.  Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin.

Authors:  Michelle M Mielke; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Ingmar Skoog; Prashanthi Vemuri; Mary M Machulda; Jonathan Graff-Radford; David S Knopman; Clifford R Jack; Ronald C Petersen; Silke Kern
Journal:  Alzheimers Dement       Date:  2019-10-23       Impact factor: 21.566

4.  Genome-wide association study of cerebrospinal fluid neurofilament light levels in non-demented elders.

Authors:  Li-Dong Niu; Wei Xu; Jie-Qiong Li; Chen-Chen Tan; Xi-Peng Cao; Jintai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2019-11

Review 5.  Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies.

Authors:  Henrik Zetterberg; Barbara B Bendlin
Journal:  Mol Psychiatry       Date:  2020-04-06       Impact factor: 15.992

6.  Neurogranin as a predictor of memory and executive function decline in MCI patients.

Authors:  Alison Headley; Andres De Leon-Benedetti; Chuanhui Dong; Bonnie Levin; David Loewenstein; Christian Camargo; Tatjana Rundek; Henrik Zetterberg; Kaj Blennow; Clinton B Wright; Xiaoyan Sun
Journal:  Neurology       Date:  2018-02-02       Impact factor: 9.910

Review 7.  The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers.

Authors:  N J Ashton; A Leuzy; T K Karikari; N Mattsson-Carlgren; A Dodich; M Boccardi; J Corre; A Drzezga; A Nordberg; R Ossenkoppele; H Zetterberg; K Blennow; G B Frisoni; V Garibotto; O Hansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-06       Impact factor: 9.236

8.  Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.

Authors:  Michelle M Mielke; Scott A Przybelski; Timothy G Lesnick; Silke Kern; Henrik Zetterberg; Kaj Blennow; David S Knopman; Jonathan Graff-Radford; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri
Journal:  Alzheimers Dement       Date:  2021-03-04       Impact factor: 16.655

Review 9.  Clinical significance of fluid biomarkers in Alzheimer's Disease.

Authors:  Piotr Lewczuk; Marta Łukaszewicz-Zając; Piotr Mroczko; Johannes Kornhuber
Journal:  Pharmacol Rep       Date:  2020-05-08       Impact factor: 3.024

Review 10.  Current state of Alzheimer's fluid biomarkers.

Authors:  José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow
Journal:  Acta Neuropathol       Date:  2018-11-28       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.